Regional Analysis

Global Peptide Receptor Radionuclide Therapy (PRRT) Market - Regional Analysis

On the basis of region, the global peptide receptor radionuclide therapy (PRRT) market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the market, owing to increasing product approval by regional drug regulatory authorities such as the U.S. FDA and Health Canada, to launch the products in the region. For instance, in January 2021, Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, global healthcare company, received the U.S. Food and Drug Administration approval for its Lutetium (177Lu) Oxodotreotide (Lutathera) drug, which is indicated for gastroenteropancreatic neuroendocrine tumor.

Moreover, Asia Pacific peptide receptor radionuclide therapy (PRRT) market is expected to hold a significant market share during the forecast period, owing to increasing treatment therapies on neuroendocrine tumor. For instance, in March 2021, according to National Canter for Biotechnology Information, the two most commonly used radio-peptides is 90Y-DOTATOC and 177Lu-DOTATATE for radionuclide therapy in neuroendocrine tumors.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa